moderna - Search News

Moderna Stock Falls

MarketWatch on MSN · 1h

Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Hosted on MSN · 17m

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

YAHOO!Finance · 29m

Moderna stock drops as Goldman Sachs cuts rating

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

SchaeffersResearch.com · 1h

Moderna Stock Falls on Vaccine Revenue Concerns

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.

Seeking Alpha on MSN · 1h

Moderna down as Goldman Sachs downgrades on revenue outlook

Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Goldman's downgrade comes days after the Cambridge,

1d

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

dermatologyadvisor1d

Moderna Receives $590M From HHS to Develop Bird Flu Vaccine

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

13d

Is Moderna a Bad-News Buy for 2025?

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

4d

Moderna Secures European Contract For Covid-19 Vaccine

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

10don MSN

Is Moderna Stock a Buy?

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results